disulfiram ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
928 97-77-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • disulfiram
  • tetraethylthiram disulfide
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
  • Molecular weight: 296.52
  • Formula: C10H20N2S4
  • CLOGP: 3.88
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.37
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 24.09 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Aug. 28, 1951 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psychiatric symptom 116.94 43.98 25 1031 5198 63482768
Intentional self-injury 111.38 43.98 33 1023 25654 63462312
Drug abuse 46.24 43.98 23 1033 72495 63415471

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Milk-alkali syndrome 121.06 30.95 22 1898 583 34954428
Alcohol intolerance 100.90 30.95 18 1902 428 34954583
Drug abuse 66.85 30.95 50 1870 99046 34855965
Psychiatric symptom 63.92 30.95 18 1902 3495 34951516
Metabolic alkalosis 52.91 30.95 13 1907 1488 34953523
Drug interaction 44.39 30.95 58 1862 225888 34729123
Hypercalcaemia 44.12 30.95 20 1900 15448 34939563
Hypertonia neonatal 43.79 30.95 9 1911 458 34954553
Agitation neonatal 36.15 30.95 9 1911 1087 34953924
Sopor 35.58 30.95 16 1904 12120 34942891
Depressed level of consciousness 34.21 30.95 24 1896 42817 34912194
Bradyphrenia 34.12 30.95 12 1908 4786 34950225
Intentional overdose 33.80 30.95 24 1896 43650 34911361
Alcohol interaction 31.54 30.95 10 1910 2903 34952108
Reduced facial expression 31.23 30.95 8 1912 1083 34953928

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psychiatric symptom 178.60 32.44 43 2812 6992 79734541
Alcohol intolerance 114.04 32.44 19 2836 466 79741067
Milk-alkali syndrome 111.68 32.44 22 2833 1398 79740135
Drug abuse 105.61 32.44 68 2787 162623 79578910
Intentional self-injury 103.02 32.44 40 2815 32379 79709154
Drug interaction 66.88 32.44 78 2777 415105 79326428
Sopor 58.78 32.44 27 2828 32983 79708550
Intentional overdose 53.56 32.44 38 2817 105922 79635611
Metabolic alkalosis 44.30 32.44 13 2842 4476 79737057
Off label use 41.24 32.44 96 2759 907119 78834414
Generalised tonic-clonic seizure 37.70 32.44 22 2833 43888 79697645
Antipsychotic drug level increased 36.60 32.44 12 2843 5945 79735588
Jarisch-Herxheimer reaction 35.67 32.44 8 2847 949 79740584
Hypercalcaemia 34.97 32.44 20 2835 38410 79703123
Psychotic disorder 33.59 32.44 20 2835 41382 79700151
Dysarthria 33.56 32.44 24 2831 67598 79673935

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07BB01 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
DRUGS USED IN ADDICTIVE DISORDERS
Drugs used in alcohol dependence
ATC P03AA04 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS
ECTOPARASITICIDES, INCL. SCABICIDES
Sulfur containing products
ATC P03AA54 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS
ECTOPARASITICIDES, INCL. SCABICIDES
Sulfur containing products
FDA MoA N0000000183 Acetyl Aldehyde Dehydrogenase Inhibitors
CHEBI has role CHEBI:24127 fungicides
CHEBI has role CHEBI:35487 aldehyde dehydrogenase (NAD) inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:37733 EC 3.1.1.8 inhibitor
CHEBI has role CHEBI:48422 angiogenesis antagonist
CHEBI has role CHEBI:50276 topoisomerase I inhibitors
CHEBI has role CHEBI:68495 Type I cell-death inducers
CHEBI has role CHEBI:73240 NF-kappaB inhibitors
CHEBI has role CHEBI:78444 Alpha-carboxylesterase inhibitor
CHEBI has role CHEBI:173085 ferroptosis inducers
MeSH PA D065086 Acetaldehyde Dehydrogenase Inhibitors
MeSH PA D000427 Alcohol Deterrents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
FDA EPC N0000175679 Aldehyde Dehydrogenase Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Alcoholism indication 7200002
Cirrhosis of liver contraindication 19943007 DOID:5082
Chronic glomerulonephritis contraindication 20917003
Alcohol intoxication contraindication 25702006
Hypothyroidism contraindication 40930008 DOID:1459
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Nephritis contraindication 52845002 DOID:10952
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Epilepsy contraindication 84757009 DOID:1826
Disease of liver contraindication 235856003 DOID:409
Cognitive Impairment following Traumatic Brain Injury contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Aldehyde dehydrogenase, mitochondrial Enzyme INHIBITOR WOMBAT-PK CHEMBL
Sodium/nucleoside cotransporter 1 Transporter Ki 5.24 DRUG MATRIX
Mu-type opioid receptor GPCR Ki 5.85 DRUG MATRIX
Translocator protein Transporter WOMBAT-PK
D(1A) dopamine receptor GPCR Ki 5.97 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.12 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 5.74 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 4.16 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 4.66 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.13 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.83 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.43 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.43 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 6.70 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 5.96 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.61 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 5.40 DRUG MATRIX
Amine oxidase [flavin-containing] A Enzyme IC50 4.86 DRUG MATRIX
Retinal dehydrogenase 1 Enzyme IC50 6.89 CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme IC50 5.32 DRUG MATRIX
C-C chemokine receptor type 5 GPCR Ki 4.74 DRUG MATRIX
C-X-C chemokine receptor type 2 GPCR Ki 5.38 DRUG MATRIX
C-C chemokine receptor type 2 GPCR Ki 6.02 DRUG MATRIX
Mitogen-activated protein kinase 3 Kinase IC50 5.82 DRUG MATRIX
C-C chemokine receptor type 4 GPCR Ki 5.36 DRUG MATRIX
Monoglyceride lipase Enzyme IC50 5.90 CHEMBL
Protein-lysine 6-oxidase Enzyme IC50 6.50 CHEMBL
Lysine-specific demethylase 5A Enzyme IC50 5 CHEMBL
Lysyl oxidase homolog 3 Enzyme IC50 7.03 CHEMBL
Lysyl oxidase homolog 4 Enzyme IC50 7.23 CHEMBL
Histone-lysine N-methyltransferase EHMT2 Enzyme IC50 6.22 CHEMBL
Histone-lysine N-methyltransferase EHMT1 Enzyme IC50 5.80 CHEMBL
Lysyl oxidase homolog 2 Enzyme IC50 6.82 CHEMBL
Gasdermin-D Unclassified IC50 6.40 CHEMBL
Fructose-1,6-bisphosphatase 1 Enzyme IC50 6.22 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 4.79 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.67 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 4.33 DRUG MATRIX
Aldehyde dehydrogenase, mitochondrial Enzyme IC50 4.40 CHEMBL
Bifunctional protein GlmU Enzyme IC50 4.07 CHEMBL
Replicase polyprotein 1ab Enzyme IC50 5.98 CHEMBL
NACHT, LRR and PYD domains-containing protein 3 Unclassified IC50 5.52 CHEMBL
Gasdermin-D Unclassified IC50 6.40 CHEMBL
Carbamate kinase, EC 2.7.2.2 Unclassified IC50 6.22 CHEMBL

External reference:

IDSource
4018494 VUID
N0000146816 NUI
D00131 KEGG_DRUG
3554 RXNORM
4018494 VANDF
C0012772 UMLSCUI
CHEBI:4659 CHEBI
CHEMBL964 ChEMBL_ID
DB00822 DRUGBANK_ID
D004221 MESH_DESCRIPTOR_UI
3117 PUBCHEM_CID
7168 IUPHAR_LIGAND_ID
1781 INN_ID
TR3MLJ1UAI UNII
2848 MMSL
4623 MMSL
d01389 MMSL
000752 NDDF
387212009 SNOMEDCT_US
39516004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 0054-0356 TABLET 250 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 0054-0357 TABLET 500 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 42794-028 TABLET 250 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 42794-029 TABLET 500 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 47781-607 TABLET 250 mg ORAL ANDA 18 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 47781-607 TABLET 250 mg ORAL ANDA 18 sections
Antabuse HUMAN PRESCRIPTION DRUG LABEL 1 54868-5034 TABLET 250 mg ORAL ANDA 18 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 60429-196 TABLET 250 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 60429-196 TABLET 250 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 62135-431 TABLET 250 mg ORAL ANDA 13 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 62135-431 TABLET 250 mg ORAL ANDA 13 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 62135-432 TABLET 500 mg ORAL ANDA 13 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 62135-432 TABLET 500 mg ORAL ANDA 13 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 64980-171 TABLET 250 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 64980-172 TABLET 500 mg ORAL ANDA 17 sections
Disulfiram HUMAN PRESCRIPTION DRUG LABEL 1 68151-2694 TABLET 250 mg ORAL ANDA 17 sections